This study suggested that patients with MetS might be at a lower risk of developing diabetes when treated with a combination of CCB (verapamil) and angiotensin-converting enzyme (ACE) inhibitor (trandolapril) (Bakris et al., 2009). The gene discussed is ACE; the disease is metabolic syndrome.